Approved Risk Evaluation and Mitigation Strategies (REMS)
PS-Mycophenolate
Shared System REMS
REMS last update: 06/01/2023
What medicines are included in the REMS?
Product Name | Application Number | Application Holder | Added to REMS | DailyMed Link | FDA Link |
---|---|---|---|---|---|
mycophenolate (Info at Drugs@FDA) | ANDA 214283 | BPI LABS | 06/01/2023 | ||
mycophenolate (Info at Drugs@FDA) | ANDA 217031 | SKG PHARMA | 11/29/2023 |
What is the purpose of the REMS?
The goal of the PS-Mycophenolate REMS is to mitigate the risk of embryofetal toxicity associated with exposure to mycophenolate during pregnancy by:
- Educating healthcare providers on the following:
- The increased risks of first trimester pregnancy loss and congenital malformations associated with exposure to mycophenolate during pregnancy.
- The need to counsel females of reproductive potential on the importance of pregnancy prevention and planning when taking mycophenolate.
- The need to report pregnancies to the PS-Mycophenolate Pregnancy Registry.
- Informing females of reproductive potential who are prescribed mycophenolate about:
- The increased risks of pregnancy loss (miscarriage) and birth defects.
- The importance of pregnancy prevention and planning when taking mycophenolate.
What do participants need to know?
Below is a general overview of the REMS for all REMS participants (e.g., patients, pharmacies, and healthcare providers). See the application holder(s) REMS Website or the approved REMS materials for more information.
View application holder(s) REMS Website
Healthcare Providers that prescribe mycophenolate-containing products:
|
What materials are included in the REMS?
The REMS includes a REMS Document. In addition, the REMS includes the following materials intended for patients and healthcare providers.
Material Name | Material Name Link |
---|---|
Prescriber Training Confirmation Form (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_Prescriber_Training_Confirmation_Form.pdf |
Center Training Confirmation Form (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_Center_Training_Confirmation_Form.pdf |
FDA Blueprint for Mycophenolate REMS Education (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_10_03_FDA_Blueprint_for_Mycophenolate_REMS_Education.pdf |
Healthcare Provider Guide (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/ PS_Mycophenolate_2023_06_01_Healthcare_ Provider_Guide.pdf |
Patient Guide (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_Patient_Guide.pdf |
PS-Mycophenolate Pregnancy Registry Frequently Asked Questions for Patients (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_PS-Mycophenolate_Pregnancy_Registry_Frequently_Asked_Questions_for_Patients.pdf |
REMS Document (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Document.pdf |
REMS Full (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Full.pdf |
REMS Letter for Healthcare Providers 1 (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Letter_for _Healthcare_Providers_1.pdf |
REMS Letter for Healthcare Providers 2 (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Letter_for _Healthcare_Providers_2.pdf |
REMS Letter for Transplant Center Directors 1 (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Letter _for_Transplant_Center_Directors_1.pdf |
REMS Letter for Transplant Center Directors 2 (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Letter _for_Transplant_Center_Directors_2.pdf |
REMS Website Screenshots (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Website_Screenshot.pdf |
Website Banner (PDF) | https://www.accessdata.fda.gov/drugsatfda_docs/rems/PS_Mycophenolate_2023_06_01_REMS_Website_Banner_Screenshot.pdf |
What assessment is available to the REMS?
Assessment Plan |
---|
REMS assessment plan unavailable for posting at this time. |
What updates have been made to the REMS?
Date | Summary of change |
---|---|
06/01/2023 | Approval of the REMS. |
Disclaimer: This webpage provides general information about REMS programs to various REMS participants (e.g., patients, pharmacies, and healthcare providers). The summary information provided herein is not comprehensive and may not include all of the information relevant to REMS participants. This webpage does not constitute a replacement, modification, or revision of the approved REMS document, including any appended REMS materials. Refer to the approved REMS document for complete information on the REMS requirements for each approved application.